MannKind looks to raise $110M

Inhaled diabetes drug developer MannKind hopes to raise as much as $110 million by lending 9 million shares of its stock to Merrill Lynch, a Bank of America holding, at $5.55 a share. Merrill Lynch will then short the stock, giving MannKind additional funding support R&D costs, and for general corporate purposes. MannKind's stock dipped on news of the stock sale. Article

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.